Gut microbiota and SCFA biomarkers for early diagnosis of PD patients and differentiation of its motor subtypesOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study tested whether gut microbiota and short-chain fatty acids (SCFAs) can support early Parkinson's disease (PD) diagnosis. A key goal was separating PD from essential tremor (ET), a common early mimic. Fecal samples were analyzed by 16S rRNA gene sequencing using both DADA2 denoising and OTU clustering. SCFAs were measured by gas chromatography-mass spectrometry. Differential taxa were found with five statistical methods, then ranked by random forest and tested with ROC curves.
Who was studied?
Participants were 104 drug-naive early PD patients, 69 ET patients, and 61 healthy controls, recruited at Ruijin Hospital in Shanghai, China. All were aged 35 to 80 years. PD patients were at Hoehn and Yahr stage 2.5 or below and took no anti-Parkinsonian drugs. PD was split into tremor-dominant and non-tremor-dominant subtypes. Samples were divided into a test set (73 PD, 48 ET, 43 controls) and a validation set (31 PD, 21 ET, 18 controls).
What were the most important findings?
Compared with healthy controls, PD showed reduced Citrobacter and Haemophilus, increased Eggerthella, and elevated isovaleric and isobutyric acids. The combined microbiota and SCFA model reached a validation AUC of 0.864. PD versus ET showed decreased Bilophila, Bacteroides, and Haemophilus, plus higher isovaleric, isobutyric, and valeric acids (validation AUC 0.825). Tremor-dominant PD was distinguished from ET (validation AUC 0.780). Tremor-dominant and non-tremor-dominant PD differed only in lower Dialister.
What are the greatest implications of this study?
Gut microbiota and SCFAs may act as non-invasive candidate biomarkers for early, drug-naive PD. They could help separate PD from essential tremor, a long-standing clinical challenge. The branched-chain fatty acid rise suggests increased protein fermentation from dysbiosis. Findings are exploratory, from a single center, with modest subtype separation, so larger multi-center cohorts are needed before clinical use.